Microsoft word - 81-84

Hamidreza Mahboobi1, 2, Tahereh Khorgoei3, Aida Najafian1 1: Reproductive Health Research Center, Hormozgan University of Medical Sciences (HUMS), BandarAbbas, Iran2: Payame Noor University (PNU), Iran3: Hormozgan Cardiovascular Research Center, Hormozgan University of Medical Sciences (HUMS),Bandar Abbas, Iran Corresponding author:
Hamidreza Mahboobi, Hormozgan University of Medical Sciences (HUMS), Bandar Abbas, Iran. Phone:
+ 98. 9364300250, E-mail:
Bibliographic information of this paper for citing:
Hamidreza Mahoobi, Tahereh Khorgoei, and Aida Najafian. Towards defining criteria for
metformin usage in management of Gestational Diabetes Mellitus. Electron. Pysicician 2010, 2:81-84,
Available at:
Received: 26 June 2010Revised: 03 July 2010Accepted: 05 July 2010Published: 07 July 2010 2009-2010 Electronic Physician Keywords: Gestational diabetes mellitus; Metformin
Dear Editor,
(2). Without treatment, GDM is associatedwith complications (3). Insulin is commonly used pregnancies (1), and pregnancy outcomes in glycemic control with medical nutritional GDM are strongly related to glucose control lowering the blood glucose as well as being teratogenic, and did not adversely affect birth length and weight, growth, or motor social development in the first 18 months of educating with regard to insulin injection before they start using it, and there is alsoalways a chance of hypoglycemia in these Although metformin seems to be as effective patients. Moreover, insulin resistance and as insulin in management of patients with insulin, there are still concerns about its safety in neonates. Randomized controlled have lead to increasing interest for the usage trials assessing metformin safety in neonates of oral hypoglycemic agents in the treatment and long-term follow-up of these neonates is lacking. Insulin is still the drug of choice in oral agents are easier to administer than up of metformin effects on neonates could insulin in clinical practice (11). However, change this role and may revolutionize the there are concerns that oral agents can cross should consider that specific patients such as teratogenesis and other fetal complications, resistance (24) may benefit more than others resistance, remains unclear (7, 12).
should be carried out on specific patients in induction of ovulation in PCOS patients (13) and is associated with a reduction ingestational pharmacokinetics of metformin in pregnantwomen is similar to those in non-pregnant REFERENCES
patients (12). Metformin was found to bereadily transferable from the maternal tofetal circuits across placentas that were Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes.
study showed that preeclampsia and prenatal Diabetic Medicine. 2004;21(2):103-13.
mortality are more common in patients who were treated with metformin in comparison HD. Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial.
these findings (21). Potential hypoglycemicagents have been shown to have no adverse 3. Langer O, Yogev Y, Most O, Xenakis EMJ.
Gestational diabetes: The consequences of not have additional benefits, including reducing treating. American Journal of Obstetrics and insulin resistance, body weight, long term risk of diabetes (23), and development of 4. Gestational Diabetes Mellitus. Diabetes Care.
2004 January 2004;27(suppl 1):s88-s90.
throughout pregnancy reduces the development Jovanovic L. Comparison of an insulin analog, of gestational diabetes in women with polycystic insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes 15. Stadtmauer LA, Wong BC, Oehninger S.
6. Jovanovic L, Ilic S, Pettitt DJ, Hugo K, Should patients with polycystic ovary syndrome Gutierrez M, Bowsher RR, et al. Metabolic and be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome-- beyond ovulation induction. Hum Reprod. 2002 7. Homko CJ, Sivan E, Reece AE. Is there a role 16. Glueck CJ, Wang P, Goldenberg N, Sieve- diabetes and type 2 diabetes during pregnancy? with polycystic ovary syndrome treated with 8. Catalano PM, Kirwan JP, Haugel-de MouzonS, King J. Gestational Diabetes and Insulin Loftspring M, Sherman A. Metformin during Implications for Mother and Fetus. J Nutr. 2003 pregnancy reduces insulin, insulin resistance, development of gestational diabetes: prospective hypoglycemic agents in pregnancy. J Matern polycystic ovary syndrome from preconception Fetal Neonatal Med. 2006 Nov;19(11):679-86.
10. Rowan JA, Hague WM, Gao W, Battin MR,Moore MP. Metformin versus insulin for the 18. Glueck CJ, Goldenberg N, Pranikoff J, treatment of gestational diabetes. N Engl J Med.
Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18months of life in 126 infants born to 109 11. Carles G, Germain L, Alassas N, El Guindi mothers with polycystic ovary syndrome who conceived on and continued metformin through gestational diabetes with oral hypoglycemic pregnancy. Hum Reprod. 2004 Jun;19(6):1323- agents]. J Gynecol Obstet Biol Reprod (Paris).
19. Nanovskaya TN, Nekhayeva IA, Patrikeeva 12. Charles B, Norris R, Xiao X, Hague W.
Population pharmacokinetics of metformin in metformin across the dually perfused human placental lobule. Am J Obstet Gynecol. 2006 20. Hellmuth E, Damm P, Molsted-Pedersen L.
Rotmensch S, Glezerman M. Neonatal outcome Oral hypoglycaemic agents in 118 diabetic in polycystic ovarian syndrome patients treated pregnancies. Diabet Med. 2000 Jul;17(7):507- with metformin during pregnancy. J Matern Fetal Neonatal Med. 2006 Jul;19(7):415-9.
14. Glueck CJ, Wang P, Kobayashi S, Phillips outcomes in women with polycystic ovarysyndrome. Diabet Med. 2004 Aug;21(8):829-36.
Diagnosis and new approaches in the therapy ofgestational diabetes mellitus. Curr Diabetes Rev.
2006 Aug;2(3):343-52.
23. Hawthorne G. Metformin use and diabeticpregnancy-has its time come? Diabet Med. 2006Mar;23(3):223-7.
24. Simmons D, Walters BN, Rowan JA,McIntyre HD. Metformin therapy and diabetesin


Strategic marketing services for the early stage business StartupFactory, LLC 6114 LaSalle Ave. • Oakland, CA 94611 • (510) 238-0800 FOR IMMEDIATE RELEASE StartupFactory, LLC tapped to lead effort for VARTA Microbattery at 2013 Medical Device & Manufacturing (MD&M West) exhibit Oakland, Calif., 12-09-2012 – StartupFactory, LLC, a strategic co

Que aprueba el protocolo de defensa de la competencia del mercosur

Hoja Nº 1/1 LEY Nº 1143 QUE APRUEBA EL PROTOCOLO DE DEFENSA DE LA COMPETENCIA DEL MERCOSUR EL CONGRESO DE LA NACION PARAGUAYA SANCIONA CON FUERZA DE Artículo 1º.- Apruébase el Protocolo de Defensa de la Competencia del Mercosur, suscrito entre los países miembros del Mercosur durante la Reunión del Consejo de Mercado Común (CMC) y Jefes de Estado, en Fortaleza, Brasi

Copyright © 2010-2014 Metabolize Drugs Pdf